Ductal carcinoma in situ (DCIS) is a non-invasive form of breast cancer that is often detected through screening programs. While patients generally have a good prognosis, treatment outcomes can vary greatly, with some cases progressing to invasive breast cancer. Radiation is a part of the standard treatment after breast-conserving surgery. Individual responses to radiation therapy differ and are possibly influenced by various molecular factors. Telomere length is also one of the potential biomarkers of predicting radiation response. Telomeres protect chromosome ends from shortening and maintain genomic stability.
This master’s thesis aimed to explore the dynamics of the leukocyte telomere length of DCIS patients undergoing radiation treatment, as well as assess the association of genetic factors with leukocyte telomere length. We also investigated the impact of telomere length and genetic factors on the occurrence of adverse events following radiation. In this longitudinal study, 89 DCIS patients were included. Genomic DNA was extracted from whole blood samples obtained before radiation treatment, immediately after and six months after radiation. Quantitative PCR was then used to determine the leukocyte telomere length. The presence of selected polymorphisms in the TERT gene was determined by competitive allele specific PCR.
Our results demonstrate that telomere length in patients with DCIS increases immediately after radiation and decreases again within six months. This finding suggests that telomere length could serve as a potential biomarker of radiation response. We also identified a statistically significant association between carriers of at least one TERT rs2736098 polymorphic T allele, with longer telomeres in leukocytes before radiation. The occurrence of adverse events following radiation was influenced by patients’ clinical characteristics. However, we did not find evidence supporting an association between studied polymorphisms and adverse events of radiation. Telomere length immediately after radiation treatment was associated with the occurrence of adverse cardiac events six months after radiation. Our results significantly contribute to establishing of telomeres as a new biomarker that could help improve the quality of life for DCIS patients and provide an important foundation for further research.
|